Bettina Brierley, chief commercial officer at Celtic Renewables, discusses commercialization of biosolvents for pharmaceutical manufacturing.
|Articles|October 1, 2004
- Pharmaceutical Technology-10-01-2004
- Volume 2004 Supplement
- Issue 7
The Integrity Tests: Choosing Diffusive Airflows of Bubble Points
Author(s)Maik W. Jornitz
This article critiques the diffusive-airflow and bubble-point tests for their comparative suitability for integrity testing in pharmaceutical processes.
Advertisement
Articles in this issue
about 22 years ago
Choosing the Proper Filterabout 22 years ago
Validation of Sterile Filtrationabout 22 years ago
Principles of Steam-In-Placeabout 22 years ago
Single-Use Technology for Sterilizing-Grade FiltrationAdvertisement
Related to this article
From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.
The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
Panelists on the PharmTech AI Pulse Check weigh a December AI playbook, EMA/MHRA moves, PCCP accountability gaps, and MCP-ready regulatory guidance.
France’s 2030 Health Initiative is driving growth in biotechnology, health innovation, biomanufacturing, and digital health.
CPHI Award winner, Pauline van der Wijst-Janssen, PhD, product development manager and global technical lead at DFE Pharma, explains excipient variability and excipients’ role in continuous manufacturing.
Pauline van der Wijst-Janssen, PhD, of DFE Pharma, won the CPHI Pharma Award for Future Leader. In this interview with PharmTech, she provides advice for scientists looking to advance to leadership roles.
Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the First Factor XIa Approval Means for Developers
2
France Remains One of Europe’s Leading Biotech Funding Hubs
3
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
4
Drapeau’s AI Deep Dive: Qualify the Reviewer Before the AI Goes Live
5